Argos Therapeutics, Inc. (NASDAQ:ARGS) shares were down 5.9% on Wednesday . The stock traded as low as $0.16 and last traded at $0.16. Approximately 1,820,596 shares changed hands during mid-day trading, a decline of 24% from the average daily volume of 2,388,278 shares. The stock had previously closed at $0.17.
Separately, Zacks Investment Research cut Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One research analyst has rated the stock with a sell rating and three have given a hold rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $4.13.
The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
What are top analysts saying about Argos Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Argos Therapeutics Inc. and related companies.